Aspire Biopharma Holdings (ASBP) Assets Average (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Assets Average for 5 consecutive years, with $10.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average rose 599.09% year-over-year to $10.3 million in Q2 2026; TTM through Jun 2026 was $10.3 million, a 599.09% increase from a year earlier, with the FY2025 full-year figure at $730077.5, down 92.75% from the prior year.
• Assets Average was $10.3 million for Q2 2026 at Aspire Biopharma Holdings, up from $4.2 million in the prior quarter.
• Over five years, Assets Average peaked at $301.6 million in Q1 2023 and troughed at $1.1 million in Q1 2025.
• A 5-year average of $100.0 million and a median of $20.0 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average slumped 94.74% in 2025 and jumped 599.09% in 2026, its largest moves.
• Over 5 years, Assets Average stood at $299.0 million in 2022, then sank by 93.33% to $19.9 million in 2023, then plunged by 32.12% to $13.5 million in 2024, then plunged by 86.27% to $1.9 million in 2025, then jumped by 456.02% to $10.3 million in 2026.
• The last three Assets Average figures came in at $10.3 million (Q2 2026), $4.2 million (Q1 2026), and $1.9 million (Q4 2025), per Business Quant data.